MedLumics, Spanish medical device company closes €34M round

, , ,
Integral service around a transaction
BY : Diego GutiérrezMarch Wed, 2017
This financing round is the largest financing round in the history of medical technology in Spain and is one of the largest rounds in Europe in the last year. Investors that have backed the company include Ysios Capital and Caixa Capital Risk.
About MedLumics

Founded in 2009, MedLumics is a company that produces camera-based cardiac devices that provide a real-time view of the heart's condition. Its Argia® technology platform, based on integrated optics, combines electrical and optical components on a small silicon chip. These products enable physicians to improve diagnostic and therapeutic procedures through optical tissue assessment.

"The Madrid-based company has already received a €3.5M round in 2011, which involved Caixa capital Risk e Ysios Capital"comments Diego Gutiérrez, corporate finance expert at Abra- invest

About the investment round

This investment round will bring its main product to the market. AblaView is the company's main product and is aimed at the treatment of atrial fibrillation, in the field of arrhythmias. AblaView represents a qualitative leap in the treatment of this disease, as for the first time doctors will have a device that will allow them to see the effect of their therapies in real time and directly.

The round was led by Edmond de Rothschild Investment Partners (EdRIP), and new investors include Seroba Life Sciences and Innogest Capital as well as Ysios Capital Partners and Caixa Capital Risc. As a result of this capital increaseThe board is joined by the founder, Eduardo Margallo and the representative of Ysios Capital, Josep Lluís Sanfeliu, Olivier Litzka on behalf of EdRIP, Claudio Rumazza for Innogest and James Greene for Seroba.

"The entry of European investors is a great opportunity for Medlumcis, which gains perspective and ease of entry into new markets. In addition, some of the investors, such as Seroba Life Science, have great experience in bringing medical technology to the market," says Diego Gutierrez.

Photonics technology devices market

 MedLumics, Spanish medical device company closes €34M round

 Other posts that may interest you

Inkemia, which is listed on the Mab, carries out a capital increase, opens a subsidiary and prepares to jump to the English Mab.

Sanitas buys Helthia to enter the world of digitalisation

List of acquisitions in medical device biotechnology

If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.


The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?